Mark Bamforth has founded, built, and sold three contract development and manufacturing organizations over the past 12 years, partnering with private equity firms.
Gallus Biopharmaceuticals focused on monoclonal antibodies, Brammer Bio produced viral vectors for gene therapy, and Arranta Bio produced microbiome, plasmid, and mRNA vaccines. In total, these companies created over 1,200 jobs, enabled more than 100 clinical trial projects for clients, and delivered two commercial products.
Previously, Bamforth spent 22 years at Genzyme, latterly running a 12-site clinical and manufacturing operation that supported over 20 commercial therapeutics and a pharmaceutical CMO business. His career began as a petroleum engineer with Britoil, followed by a stint as a chemical engineer with Whitbread.
Bamforth serves on the boards of CONTINUUS Pharma, Enterobiotix, Inceptor Bio, Pneumagen, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.